The HIV Protease Inhibitor Nelfinavir Downregulates Akt Phosphorylation by Inhibiting Proteasomal Activity and Inducing the Unfolded Protein Response  by Gupta, Anjali K. et al.
The HIV Protease Inhibitor Nelfinavir Downregulates Akt
Phosphorylation by Inhibiting Proteasomal Activity
and Inducing the Unfolded Protein Response1
Anjali K. Gupta, Bin Li, George J. Cerniglia, Mona S. Ahmed, Stephen M. Hahn and Amit Maity
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
Abstract
HIV protease inhibitors (HPIs), which have been used
to treat HIV patients since the mid 1990s, have been
shown to downregulate the phosphatidylinositol 3-
kinase (PI3K)–Akt pathway. Because this pathway is
frequently activated in human malignancies and asso-
ciated with resistance to ionizing radiation, we inves-
tigated and confirmed that HPIs could radiosensitize
cells. However, the mechanism underlying this down-
regulation was unclear, prompting the investigations
in this report. In this paper we show that nelfinavir in-
hibits proteasome activity. Inhibition of the proteasome
leads to endoplasmic reticulum–based stress with ac-
cumulation of misfolded proteins, which triggers the
unfolded protein response (UPR). As part of the UPR,
the alpha subunit of eukaryotic translation initiation
factor 2 (eIF2A) is phosphorylated, resulting in a de-
crease in global protein synthesis and induction of the
feedback regulator growth arrest and DNA damage-
inducible protein (GADD34), which acts as a phos-
phatase in complex with protein phosphatase 1. This
complex dephosphorylates eIF2A; however, our data
also suggest that this phosphatase activity can de-
phosphorylate Akt. Furthermore, our data indicate that
nelfinavir decreases Akt phosphorylation by triggering
this response. These findings may have important im-
plications in understanding how nelfinavir may increase
radiation sensitivity and also result in downregulation
of the PI3K/Akt pathway.
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Introduction
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is
thought to play an important role in the development of
cancers possibly through effects on cell proliferation, adhe-
sion, migration, invasion, apoptosis, and angiogenesis [1,2].
Activation of this pathway is very common in human can-
cers. This can occur through direct mechanisms such as
amplification/mutation of the PI3K subunits [3,4] or Akt
overexpression [5]. The PI3K/Akt pathway can also be in-
directly activated in cancers through loss of phosphatase
and tensin homolog deleted on chrorose 10 protein [2,6],
mutation of Ras [7,8], and mutation/amplification of the epider-
mal growth factor receptor (EGFR) [9,10]. We and others
have shown that activation of the PI3K/Akt pathway in human
cancers results in resistance to ionizing radiation both in cells
in tissue culture and in tumor xenografts in vivo [11–14]. For
this reason, we have been interested in targeting this pathway
as a means of increasing radiation sensitivity. Because the
PI3K/Akt pathway is so commonly activated in tumors but not
in normal tissues, inhibition of this pathway should offer some
selectivity in the treatment of many cancers. There is currently
a great deal of ongoing research to develop drugs targeting the
PI3K/Akt pathway that are safe to use in people. In a pre-
vious article, we reported that HIV protease inhibitors (HPIs),
including nelfinavir, could decrease Akt phosphorylation and
increase the sensitivity of cells to radiation [15]. We tested five
first-generation HPIs and found that three of them (nelfinavir,
amprenavir, saquinavir) inhibited Akt signaling [15]. Of the
three, we felt nelfinavir was the most efficacious. However,
the mechanism by which nelfinavir decreases Akt phosphory-
lation remains unclear.
The HPIs are peptidomimetics that inhibit the HIV aspartyl
protease, a retroviral enzyme that cleaves the viral gag-pol poly-
protein and is necessary for the production of infectious viral
particles [16]. These drugs have been used for over a decade
to treat patients with HIV infection and are fairly safe. However,
they are associated with lipid and metabolic disturbances in-
cluding hyperlipidemia, insulin resistance, peripheral lipoatrophy,
central fat accumulation, and hepatic steatosis [17]. Akt, espe-
cially the Akt2 isoform [18], plays a key role in the coordinated
regulation of growth and metabolism by the insulin/insulinlike
growth factor signaling pathway [19]. Therefore, it is possible
that the insulin resistance caused by the HPIs could be related
to the decrease in Akt phosphorylation that we have noted.
Data are emerging that the first-generation HPIs (including
nelfinavir) inhibit proteasome function [20,21]. Parker et al. [20]
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have found that nelfinavir inhibits the chymotryptic activity of
the 20S proteasome by 50% at 4 mmol/l. The proteasome
performs a surveillance function by controlling proteolysis of
regulatory proteins, such as those involved in cell cycle
progression and apoptosis. Inhibition of the proteasome
leads to excessive accumulation of misfolded proteins in
the endoplasmic reticulum (ER). This leads to the unfolded
protein response (UPR) [20], which serves to alleviate ER
stress [22,23]. Under nonstress conditions, immunoglobulin
heavy chain binding protein (BiP) (also known as GRP78) is
bound to the ER-luminal domains of a number of transmem-
brane kinases including RNA-dependent protein kinase-
like ER kinase (PERK) preventing its activation [24]. After
excessive accumulation of proteins in the ER, BiP prefer-
entially binds to unfolded proteins and dissociates from
PERK, thereby rendering the latter active [24]. PERK then
dimerizes and phosphorylates eukaryotic translation ini-
tiation factor 2a (eIF2a) on serine 51 [24]. Phosphorylated
eIF2a (P-eIF2a) globally decreases protein synthesis, there-
by providing the stressed cells time to clear misfolded pro-
teins from the ER and facilitate recovery [25,26]. P-eIF2a
also increases translation of a few UPR-related transcripts
such as those encoding activating transcription factor 4 and
growth arrest and DNA damage-inducible protein (GADD34)
[24]. GADD34 complexes with PP1 to form a phosphatase
that functions in a negative feedback loop to reverse eIF2a
phosphorylation and limit the UPR [27].
In this study we explore the effect of nelfinavir on ER
stress and on the expression of various downstream pro-
teins including P-eIF2a, PP1, GADD34, and BiP. We relate
this to the dephosphorylation of Akt and construct a model
in which nelfinavir’s effect on Akt is related to its induction
of the UPR. Understanding how nelfinavir decreases Akt
phosphorylation may have important implications in under-
standing how the drug leads to insulin resistance, or in
designing drugs that are better radiosensitizers.
Methods
Cells
SQ20B cells were obtained from American Type Culture
Collection (Rockville, MD). They were cultured in DMEM
(Fisher Scientific, Pittsburgh, PA) supplemented with 10%
FBS (Atlanta Biologicals, Norcross, GA), penicillin (100 U/ml),
and streptomycin (100 mg/ml) (Gibco/BRL, Gaithersburg,
MD) at 37jC in humidified 5% carbon dioxide–95% air.
SQ20B cells were transfected with the plasmids myc-
tagged PP1 (T320A) (kindly provided by Dr. Xu Wanping
from Dr. Necker’s Lab, National Cancer Institute, Bethesda,
MD) [28] and Flag-tagged GADD34 (generously released
by Dr. David Ron, New York University) [29] using lipo-
fectamine (Invitrogen, Carlsbad, CA) according to the manu-
facturer’s instructions.
Drugs
Nelfinavir was bought for research use from the inpatient
pharmacy at the Hospital of the University of Pennsylvania.
Nelfinavir came as solid caplets. It was ground into a fine
powder and subsequently dissolved in 100% ethanol.
LY294002, tunicamycin, thapsigargin, okadaic acid, calyculin
A, MG132, and cyclohexamide were purchased from Sigma-
Aldrich (St. Louis, MO).
Western Blotting
Cells were lysed without trypsinization by rinsing culture
dishes once with PBS followed by lysis with reducing Laemlli
sample buffer. Samples were boiled, sheared, clarified by
centrifugation, and stored at 20jC. Samples containing
equal amounts of protein were separated on a 12% SDS–
polyacrylamide gel and blotted onto nitrocellulose mem-
branes. Membranes were blocked in PBS containing 0.1%
Tween 20 and 5% powdered milk before addition of primary
antibody. Polyclonal antibodies against Akt, phospho-Akt
(Ser473), eIF2a, phospho-eIF2a, and phospho-PERK were
purchased from Cell Signaling (Danvers, MA). Monoclonal
antibodies against b-actin and FLAG (M2) were obtained
from Sigma-Aldrich. Monoclonal antibody against c-myc
(4E10), polyclonal antibodies against GADD34, CHOP
(GADD153), and BiP (GRP78) were from Santa Cruz Bio-
technology (Santa Cruz, CA). Polyclonal antibody against
PP1 was from Calbiochem (San Diego, CA). All anti-
bodies were diluted 1:1000 in 5% milk in PBS-T overnight
at 4jC. Antibody binding was detected using the ECL
chemiluminescence kit (Amersham, Arlington Heights, IL).
Images were digitized using an Arcus II scanner, and fig-
ures were assembled with Adobe Photoshop 3.0 and Micro-
soft Power Point.
Radiation Survival Determination
Cells in exponential growth phase were counted and
plated in 60-mm dishes containing 4 ml of medium. The cells
were allowed to attach and drugs were added to cultures at
least 1 hour before radiation. Cells were irradiated with a
Mark I cesium irradiator (J.L. Shepherd, San Fernando, CA)
at a dose rate of 1.6 Gy/min. Colonies were stained and
counted 10 to 14 days after irradiation. A colony by definition
had >50 cells. The surviving fraction was calculated by
dividing the number of colonies formed by the number of
cells plated times plating efficiency. Each point on the
survival curve represents the mean surviving fraction from
at least three replicates.
Immunoprecipitation
SQ20B cells were treated with vehicle (ethanol) and
10 mmol/l nelfinavir for 24 hours, washed in PBS, and lysed
in RIPA buffer (20 mmol/l Tris, pH 7.5, 150 mmol/l NaCl,
1 mmol/l EDTA, 1 mmol/l EGTA, 1% Triton X-100, 2.5 mmol/l
sodium pyrophosphate, 1 mmol/l b-glycerol phosphate,
1 mmol/l Na3VO4, 1 mg/ml leupeptin, and 2 mmol/l PMSF).
Sample lysates were collected and cleared. Cell lysates
(250 mg) were immunoprecipitated with 2.5 mg Akt or PP1
antibody overnight at 4jC. This was then rocked with 20 ml
slurry of Protein A beads (Invitrogen) for 2 hours at 4jC.
Beads were washed four times with RIPA buffer, boiled in
6 SDS-PAGE sample buffer and run on 10% SDS-PAGE
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gel. Protein was transferred to nitrocellulose then blotted for
Akt and PP1.
[35S]Methionine Incorporation Assays
Cells were treated for 24 hours with nelfinavir, then the
procedure outlined by Koumenis et al. [30] was followed. In
brief, cells were harvested and equal numbers of cells (5 
105) were plated into 60-mm dishes in media that contained
no methionine to ensure optimal incorporation of [35S]me-
thionine. After 10 hours in methionine-free media, cells were
labeled with [35S]methionine (50 mCi/ml) for 30 minutes. Cells
were washed three times with PBS, scraped off the dishes in
PBS, and centrifuged at 5000g. The cell pellet was resus-
pended in PBS containing 2 mmol/l EDTA and lysed by three
rounds of freeze-thawing. TCA precipitation of macromole-
cules and scintillation counting were performed as follows:
Briefly, 10 ml of sample was added to a mixture of 250 ml
of water, 50 ml of BSA (1 mg/ml), and 100 ml of TCA (50%,
wt/vol). The samples were kept on ice for <20 minutes and
then filtered through glass filters (GC filters, VWR Scientific,
West Chester, PA) under vacuum. The filter was washed
three times with ice-cold TCA (5%, wt/vol) and with ethanol
(95%, vol/vol) and then immersed into 5 ml of scintillation
liquid (Ecolume, ICN, Costa Mesa, CA). Disintegrations per
minute were calculated as the percentage of [35S]methionine
incorporation relative to that incorporated by untreated cells.
Results were normalized as the percent increase or de-
crease of [35S]methionine incorporation compared with that
of untreated control cells.
Proteasome Activity
SQ20B cells were plated on 100-mm dishes and treated
for 24 hours with nelfinavir at various concentrations (0, 5,
10, 15, or 20 mmol/l). Cell lysates were collected and assayed
for 20S proteasome activity as detailed in Calbiochem’s
(San Diego, CA) proteasome isolation kit (cat. no. 539176).
Briefly, this kit uses proteasome affinity beads that bind the
proteasome in equal amount of protein. The beads are
washed and incubated in a reaction buffer containing a
fluorogenic substrate such as Suc-Leu-Leu-Val-Tyr-AMC
(Calbiochem, cat. no. 539142) to measure the proteolytic
activity of the proteasome on the affinity beads. This is
compared to an AMC standard curve, which was done as
described in a Chemicon International (Temecula, CA) 20S
proteasome activity assay kit (cat. no. APT280). As a control,
treatment with MG132 was used.
Results
Nelfinavir Inhibits Akt, Results in Radiation Sensitization,
and Inhibits the Proteasome
Western blot analysis shows that nelfinavir (10–20 mmol/l)
was able to downregulate Akt phosphorylation as could the
PI3K inhibitor LY294002 (Figure 1A). We have previously
published that 5 mmol/l could also downregulate Akt but
with longer treatment (3 days) [15]. We performed clono-
genic kill curves with nelfinavir and LY294002 individually
and in combination. Both drugs sensitized SQ20B cells to
radiation (Figure 1B), but the combination gave no additive
effect, suggesting that they work through the same path-
way. We measured 20S proteasome activity in SQ20B cells
after treatment with nelfinavir for 24 hours (Figure 1C).
Nelfinavir concentrations of 5 mmol/l resulted in 30% less
proteasome activity with a leveling of dose response in the
5- to 15-mmol/l range.
SQ20B Cells Exhibit ER Stress and UPR with Nelfinavir
To show that there was a relationship between down-
regulation of Akt phosphorylation and proteasomal inhibition,
SQ20B cells were treated for 24 hours with 0 to 40 mmol/l
of nelfinavir (Figure 2A). Dephosphorylation of the Ser473
site of Akt starts at 5 mmol/l and is complete by 40 mmol/l.
Figure 1. Nelfinavir inhibits Akt, results in radiation sensitization and inhibits
the proteasome. (A) SQ20B cells were treated with LY294002 (LY) or nelfinavir
(Nfv) at the indicated concentrations or control carrier (C). Twenty-four hours
later, cells were harvested and Western blotting was performed for P-Ser Akt
or -actin (loading control). (B) SQ20B cells were plated and allowed to attach
for 4 hours. Cells were then treated with nelfinavir (5 mol/l) and/or LY294002
(10 mol/l). One hour later, they were irradiated. Ten to 14 days later, dishes
were stained and colonies were counted. (C) 20S proteasome activity in
SQ20B cells was measured with a Calbiochem proteasome isolation kit (cat.
no. 5339176) after treatment with 0 to 20 mol/l nelfinavir for 24 hours.
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The total Akt level also decreased with high concentra-
tions of nelfinavir, perhaps due to the exaggeration of the
attenuation of global protein synthesis. There was no de-
crease in total Akt at the 5- to 10-mmol/l range even after
treatment for 3 days (data not shown). Phosphorylation
of eIF2a, hallmark of the UPR, started at 5 mmol/l, peaked
at 10 mmol/l, but then subsequently decreased in associa-
tion with increased expression of GADD34, which in com-
plex with PP1 forms a phosphatase that negatively regulates
P-eIF2a. The levels of BiP and PP1 did not change. We
then treated SQ20B cells with 10 mmol/l nelfinavir and har-
vested protein at different time points (0–24 hours) after
Figure 2. Nelfinavir induces proteins associated with ER stress and the UPR. In (A) to (D), SQ20B cells were seeded, then exposed to drug 4 hours later. (A) Cells
were treated with nelfinavir (Nfv) at the indicated concentrations. Twenty-four hours later, protein samples were harvested. (B) Cells were treated with 10 mol/l
nelfinavir. At the times indicated, protein samples were harvested from replicate dishes for protein. (C) Cells were treated with 1 mol/l of the proteasomal inhibitor
MG132. At the times indicated, protein samples were harvested from replicate dishes. (D) Cells were treated with either tunicamycin or thapsigargin at the indicated
concentrations. Twenty-four hours later, protein samples were harvested. In (A) through (D), Western blotting was performed for using antibodies as indicated. (E)
[35S]Methionine incorporation assays were performed on SQ20B cells treated with the indicated concentration of nelfinavir for 24 hours. Sixty minutes before the
end of treatment, cells were labeled with [35S]methionine (50 Ci/ml). Results were normalized as the percent increase or decrease of [35S]methionine
incorporation compared with untreated control cells.
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treatment (Figure 2B). There was a decrease in P-Akt with
increased duration of time of exposure to nelfinavir but
without change in total Akt levels. By 24 hours, we saw
increased phosphorylation of PERK and eIF2a. In addition,
at 24 hours, we started seeing expression of GADD34.
After 72 hours of exposure to 10 mmol/l nelfinavir, there
was complete downregulation of P-Akt with accompanying
decrease in P-eIF2a and an increase in GADD34 (data
not shown); however, the levels of BiP and PP1 did not
change. Therefore, these data demonstrate that, in a dose-
and time-dependent manner, the downregulation of P-Akt
correlates with ER stress as manifested by P-eIF2a and
subsequent translation of GADD34.
If the effects of nelfinavir on Akt phosphorylation are
indeed mediated by proteasomal inhibition, then a proteaso-
mal inhibitor should have the same effect. MG132 is a known
inhibitor of the proteasome [31]. We treated SQ20B cells with
1 mmol/l MG132 and harvested protein at 0 to 24 hours
(Figure 2C). Akt phosphorylation was downregulated by
24 hours and corresponded to a increase in P-eIF2a and
induction of GADD34. PP1 levels remain constant although
the level of BiP does increase.
To demonstrate that the coupling of P-Akt downregulation
to UPR induction was not isolated to nelfinavir and MG132,
we used the agents tunicamycin and thapsigargin, which are
widely used for induction of the UPR in cell culture. Tunica-
mycin depletes intracellular calcium stores to trigger the
UPR, whereas thapsigargin inhibits protein glycosylation
[32,33]. Figure 2D shows that both tunicamycin and thapsi-
gargin could decrease P-Akt to undetectable levels with in-
creasing concentrations of the drugs. The decrease in Akt
phosphorylation was accompanied by induction of the UPR
as evidenced by the phosphorylation of eIF2a and transla-
tion of GADD34 and BiP (Figure 2D). These results further
support the hypothesis that one cell pathway couples P-Akt
downregulation with UPR induction in SQ20B cells.
Another hallmark of UPR induction is a global reduction in
protein synthesis. To verify that nelfinavir induced ER stress,
we measured new protein synthesis with [35S]methionine
labeling in SQ20B cells treated with varying concentrations
of the drug (Figure 2E ). Figure 2E shows that there was a
dose-dependent decrease in protein synthesis. At doses of 5
and 10 mmol/l, new protein synthesis was decreased to 66%
and 40%, respectively, of that seen in control cells. However,
even this level of decrease in protein synthesis was insuffi-
cient to cause SQ20B cells to undergo apoptosis or retard
the growth of SQ20B cells (data not shown).
PP1 but Not PP2A Mediates Akt Phosphorylation
Because there was a temporal correlation between
dephosphorylation of Akt and the induction of GADD34,
which in complex with PP1 has phosphatase activity toward
eIF2a, we wanted to see whether Akt might be a target of
the GADD34/PP1 phosphatase. Cells were pretreated with
calyculin A, which inhibits PP1, then exposed to nelfinavir
(Figure 3A). Nelfinavir downregulated Akt phosphorylation
when cells were pretreated with 0 or 1 nmol/l calyculin,
neither of which affected the level of PP1. However, with
higher doses of calyculin (>10 nmol/l), the level of PP1
decreased and the phosphorylation of eIF2a increased, as
expected. There was a concomitant increase in the phos-
phorylation of Akt, and its phosphorylation was no longer
responsive to nelfinavir. In the first four lanes of this blot
we do not see eIF2a phosphorylation with nelfinavir treat-
ment alone because the signal with calyculin was so high;
the film had to be removed quickly. However, with longer
exposure, we do see eIF2a phosphorylation with nelfinavir
alone (data not shown). Calyculin inhibits PP2A as well as
PP1; therefore, we also treated cells with okadaic acid, which
is a more specific inhibitor of PP2A. We saw no difference
in P-eIF2a or P-Akt with the addition of okadaic acid to
nelfinavir compared with nelfinavir alone (data not shown).
To confirm that inhibition of PP1 by calyculin also reverses
the P-Akt downregulation that occurs in response to a known
inducer of the UPR, SQ20B cells were pretreated with
calyculin or okadaic acid followed by treatment with tunica-
mycin. In Figure 3B, calyculin completely abolished P-Akt
downregulation, dramatically increased eIF2a phosphoryla-
tion, and decreased PP1 levels. In contrast, treatment with
okadaic acid had little or no effect on the levels of P-Akt and
P-eIF2a. Collectively, these data support the idea that PP1
can function as part of a phosphatase that can dephosphory-
late both eIF2a and Akt.
Figure 3. Inhibition of PP1 reverses the effect of nelfinavir on Akt phos-
phorylation. SQ20B cells were seeded, then exposed to drug 4 hours later.
(A) Cells were pretreated with calyculin A (CA) at the indicated concentration
for 1 hour before treatment with nelfinavir (10 mol/l). Twenty-four hours later,
protein was harvested. (B) SQ20B cells were pretreated with calyculin A or
okadaic acid (OA) at the indicated concentration for 1 hour before treatment
with tunicamycin (1.5 g/ml). Twenty-four hours later, protein was harvested.
In (A) and (B), gel electrophoresis was performed followed by Western
blotting using antibodies as indicated.
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GADD34 Induction Promotes Downregulation of Akt
in SQ20B Cells
Although our results suggest that the activation of PP1
phosphatase is responsible for P-Akt downregulation in
SQ20B cells, PP1 protein levels remained unchanged with
treatment with nelfinavir, MG132, tunicamycin, and thapsi-
gargin, indicating that eIF2a phosphatase activity was not
regulated by the UPR by altering translation of PP1. We also
analyzed PP1 phosphorylation, which is another means of
regulating PP1 activity, and this was unchanged during UPR
activation (data not shown). PP1 can also bind to its sub-
strates such as Akt, which would be another mechanism by
which Akt activity could be modulated [28,34]. We first
confirmed that the treatment with the drug for 24 hours did
not change the level of either PP1 or total Akt (Figure 4A). To
study whether nelfinavir perturbed the association between
Akt and PP1, we performed coimmunoprecipitations using
cell lysates from control or nelfinavir-treated SQ20B cells
(Figure 4B). Compared with 10% input, which represents
equal loading of Akt and PP1, no obvious changes in the
association between Akt and PP1 were detected with nelfi-
navir treatment. Both antibodies could coimmunoprecipitate
equal amounts of Akt and PP1 from control and nelfinavir-
treated cells. These results indicate that nelfinavir does not
lead to Akt dephosphorylation by changing the interaction
between PP1 and Akt.
In complexwith PP1,GADD34 dephosphorylates P-eIF2a
[27]. Others have found that GADD34 expression is induced
late in the UPR [24], presumably as a negative feedback
mechanism to limit eIF2a activity by promoting its dephos-
phorylation. We have also observed that GADD34 expres-
sion was induced with activation of UPR signaling elicited
by the different reagents including nelfinavir, MG132, thapsi-
gargin, and tunicamycin (Figure 2). This induction occurred
with a direct temporal correlation with dephosphorylation
of Akt, suggesting that there might be a cause and effect
relationship. To confirm the role of GADD34 in the down-
regulation of P-Akt, we transfected SQ20B cells with
GADD34 cDNA or a constitutively active mutant of PP1
(T320 in which the phosphorylation site has been mutated
from T to A). The Western blots in Figure 5 demonstrate
that P-Akt levels in either of these two transfectants were
significantly lower than in the vector control. Therefore, Akt
is dephosphorylated in response to increased PP1 phos-
phatase activity. Treatment with nelfinavir further down-
regulated P-Akt. As expected, the phosphorylation of eIF2a
was decreased in cells transfected with GADD34; surprisingly,
this did not occur in cells transfected with PP1(T320). A
possible explanation for this is that the point mutation may
prevent binding of the GADD34-PP1 (T320A) complex to
eIF2a but not to Akt.
Discussion
We have been interested in understanding the mechanism
by which the protease inhibitor nelfinavir decreases Akt
phosphorylation. The primary impetus for this has been our
finding that tumor cells can be radiosensitized by the drug
both in vitro and in vivo. Because nelfinavir has been used for
over a decade in the treatment of HIV patients with an
acceptable toxicity profile, it has the potential of being moved
quickly into clinical trials to be tested as a radiosensitizer. Our
previous results suggest that the ability of nelfinavir to radio-
sensitize is dependent on its downregulation of P-Akt [15].
Therefore, we were very interested in determining how this
downregulation occurred mechanistically. Our model as to
how nelfinavir leads to Akt dephosphorylation is shown in
Figure 6. Nelfinavir inhibits the proteasome (Figure 1C) at
similar concentrations (micromolar) achievable in the serum
Figure 4. Inhibition of PP1 reverses the effect of nelfinavir on Akt phos-
phorylation. (A) SQ20B cells were seeded. Four hours later, they were treated
with 10 mol/l nelfinavir (Nfv). Twenty-four hours later, protein was harvested
and subjected to gel electrophoresis. Western blotting was performed for
Akt and PPI1. (B) Same as in (A) except after 24 hours of nelfinavir treat-
ment, cells were lysed in RIPA buffer and immunoprecipitation was performed
using antibody against either Akt (left) or PP1 (right). Immunoprecipitated
proteins were run on gel electrophoresis and Western blotting was per-
formed for both Akt and PP1.
Figure 5. Expression of GADD34 or constitutively active PP1 decreases Akt
phosphorylation. SQ20B cells were transfected with empty vector or vector
expressing either PP1(T320) (constitutively active mutant) or GADD34.
Twenty-four hours later, cells were exposed to nelfinavir (10 mol/l). Twenty-
four hours later, cells were harvested for protein and gel electrophoresis was
performed followed by Western blotting using antibodies as indicated.
276 Nelfinavir Inhibits Akt Signaling Gupta et al.
Neoplasia . Vol. 9, No. 4, 2007
of patients on the drug [35] and at the same doses at which
Akt phosphorylation is inhibited. Although this does not prove
that proteasomal inhibition/ER stress is required for Akt
dephosphorylation by nelfinavir, this idea is supported by
the fact that structurally unrelated agents that inhibit the
proteasome (MG132) or induce ER stress (thapsigargin,
tunicamycin) also decrease Akt phosphorylation (Figure 2,
C and D). Nelfinavir induces ER stress, which leads to
phosphorylation of eIF2a and global inhibition of protein
synthesis. However, the synthesis of selected proteins such
as GADD34 is actually increased under ER stress. GADD34,
in complex with PP1, dephosphorylates eIF2a as part of a
negative feedback loop. We observed a temporal correlation
between GADD34 induction and P-Akt downregulation, sug-
gesting that there might be a cause and effect relationship
between the two. To show this, we performed transfections
with GADD34 and constitutively active PP1 and found that
both of these also downregulated P-Akt. These results do not
specifically place the GADD34/PP1 phosphatase activity
downstream of nelfinavir. However, treatment of cells with
calyculin A, which inhibits both PP1 and PP2A, increased Akt
phosphorylation and made the cells refractory to nelfinavir.
This result indicates that either PP1 or PP2A likely lies
between nelfinavir and Akt dephosphorylation. We repeated
the experiment using okadaic acid, which has a unique
activity profile against phosphatases. Okadaic acid in-
hibits PP2A at low concentrations (IC50 <0.1 nmol/l), but it
inhibits both PP2A and PP1 at higher concentrations (IC50 =
150 nmol/l) [28]. At a concentration of up to 100 nmol/l,
okadaic acid has no effect on Akt phosphorylation (Fig-
ure 3B), ruling out PP2A as the responsible phosphatase.
Taken together with the transfection data with PP1, we con-
clude that PP1 is the phosphatase that dephosphorylates
Akt in response to nelfinavir.
Several investigators have implicated PP2A in regulating
Akt phosphorylation [36–38]; however, these studies were
all performed on cells of nonepithelial origin. In contrast, our
okadaic results suggest that PP1, not PP2A, is the relevant
phosphatase.Consistentwith our results, Xuet al. [28] showed
in SKBR3 breast carcinoma cells that endogenous Akt and
PP1 associated with each other. They also showed that
transient overexpression of constitutively activePP1promoted
Akt dephosphorylation, and, using an in vitro phosphatase
assay, they confirmed that Akt is a substrate of PP1.
It is interesting that other agents currently in clinical trial
such as bortezomib (PS341) also exert antitumor activity by
inhibiting the proteasome, leading to the UPR [39]. Further-
more, in one study, the level of phosphorylated Akt was
decreased in a dose-dependent manner with bortezomib
[40]. Bortezomib has been approved for use in relapsed or
refractory multiple myeloma as single-agent therapy. The
grade 3/4 toxicity associated with it include thrombocytope-
nia (29%), diarrhea (11%), anemia (11%), and neutropenia
(10%) [41]. The toxicity seen with nelfinavir in HIV patients
within 1 to 2 months of use are mostly gastrointestinal
and consists of grade 1/2 diarrhea (57%) and, occasionally,
grade 3/4 (9%), which readily responds to antidiarrheal
medication and rarely requires discontinuation of nelfinavir
[35]. We also did not see single-agent activity, changes in
the growth rate, or apoptosis in tumor cells with nelfinavir
at clinically relevant doses. At higher doses (20–40 mmol/l)
we clearly saw apoptosis with nelfinavir alone. We propose
a dual-hit hypothesis of radiation sensitization. In solid tumor,
we can exert a low-grade stress response with nelfinavir, and
the addition of radiation results in increased cell kill. It is
possible bortezomib therapy at lower doses would also result
in decreased toxicity and radiosensitization.
In summary, we have shown that the HIV protease in-
hibitor nelfinavir decreases Akt phosphorylation indirectly
by inhibiting the proteasome and triggering the UPR re-
sponse. This results in radiosensitization at clinically rele-
vant doses of nelfinavir. The toxicity and safety profile of
nelfinavir has been well studied since the mid 1990s. It is
clinically poised for a trial with radiation. In the meantime,
knowledge of the mechanism by which nelfinavir results in
radiation sensitization may be useful in designing newer
Figure 6. Model of Akt dephosphorylation by nelfinavir. Nelfinavir induces ER stress and the unfolded response (UPR). As part of this response, protein translation
is globally inhibited as a result of phosphorylation of eIF2a. However, expression of selected proteins such as activating transcription factor 4 and GADD34 is
actually increased. GADD34 complexes with PP1 to form a phosphatase that dephosphorylates eIF2a and, according to our hypothesis, Akt as well.
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agents that might have even less toxicity and might be more
effective radiosensitizers.
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